The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Candida Urinary Tract Infections—Treatment
Abstract
In many instances a report from the clinical laboratory indicating candiduria represents colonization or procurement contamination of the specimen and not invasive candidiasis. Even if infection of the urinary tract by Candida species can be confirmed, antifungal therapy is not always warranted. Further investigation may reveal predisposing factors, which if corrected or treated, result in the resolution of the infection. For those with symptomatic urinary tract infections (UTIs), the choice of antifungal agent will depend upon the clinical status of the patient, the site of infection, and the pharmacokinetics and pharmacodynamics of the agent. Because of its safety, achievement of high concentrations in the urine, and availability in both an oral and intravenous formulation, fluconazole is preferred for the treatment of Candida UTIs. Flucytosine is concentrated in urine and has broad activity against Candida spp, but its use requires caution because of toxicity. Low-dose amphotericin B may be useful for Candida UTIs in selected patients. The role of echinocandins and azoles that do not achieve measurable concentrations in the urine is not clear. Small case series note some success, but failures have also occurred. Irrigation of the bladder with antifungal agents has limited utility. However, with fungus balls, irrigation of the renal pelvis through a nephrostomy tube can be useful in combination with systemic antifungal agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Pappas, P. G., Kauffman, C. A., Andes, D., Benjamin, D. K., Calandra, T. F., Edwards, J. E., Filler, S. G., Fisher, J. F., Kullberg, B.-J., Zeichner, L. O., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/596757 · Cited by 3,191 · cited 1×
“daily; or micafungin, 100 mg daily) [21].”
Self-citationVermes, A. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.2.171 · Cited by 803
Grant, S. M., & Clissold, S. P. (1990) · Drugs · doi:10.2165/00003495-199039060-00006 · Cited by 661
Pfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521
Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients
Kauffman, C. A., Vazquez, J. A., Sobel, J. D., Gallis, H. A., McKinsey, D. S., Karchmer, A. W., Sugar, A. M., Sharkey, P. K., Wise, G. J., Mangi, R., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313583 · Cited by 483
Self-citationCandiduria: A Randomized, Double-Blind Study of Treatment with Fluconazole and Placebo
Sobel, J. D., Kauffman, C. A., McKinsey, D., Zervos, M., Vazquez, J. A., Karchmer, A. W., Lee, J., Thomas, C., Panzer, H., Dismukes, W. E., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313580 · Cited by 343 · cited 4×
“reserved for those patients who have solid clinical evidence of infection of the kidney or collecting system or disseminated candidiasis [6, 17].”
InfluentialSelf-citationPetri, M. G., König, J., Moecke, H. P., Gramm, H. J., Barkow, H., Kujath, P., Dennhart, R., Schäfer, H., Meyer, N., Kalmar, P., et al. (1997) · Intensive Care Medicine · doi:10.1007/s001340050334 · Cited by 185
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177 · cited 1×
“Posaconazole has demonstrated efficacy in a murine model of hematogenous renal parenchymal candidiasis [62].”
Ikeda, F., Wakai, Y., Matsumoto, S., Maki, K., Watabe, E., Tawara, S., Goto, T., Watanabe, Y., Matsumoto, F., & Kuwahara, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.614-618.2000 · Cited by 147
Macphail, G. L. P., Taylor, G. D., Buchanan‐Chell, M., Ross, C., Wilson, S., & Kureishi, A. (2002) · Mycoses · doi:10.1046/j.1439-0507.2002.00741.x · Cited by 119
Leu, H.-S., & Huang, C.-T. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.5.1152 · Cited by 93
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Self-citationCandida auris: a Review of the Literature
Jeffery-Smith, A., Taori, S. K., Schelenz, S., Jeffery, K., Johnson, E. M., Borman, A., Candida auris Incident Management Team, Manuel, R., & Brown, C. S. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-17 · Cited by 595
Antifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
Optimizing antifungal choice and administration
Andes, D. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761135 · Cited by 63
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
Kim, K., Zilbermintz, L., & Martchenko, M. (2015) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-015-0090-4 · Cited by 48
“Unfortunately, 30 % of Candida isolates are resistant to all antifungal treatments [6].”
Background
Metadata
- Authors
- Fisher, J. F., Sobel, J. D., Kauffman, C. A., & Newman, C. A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-05-15
- Volume
- 52
- Issue
- suppl_6
- Pages
- S457-S466
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2129924373
- Cited by
- 215
- References
- 12
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.